# CJC-1295 FAQ — Common Questions on the GHRH Analog Research Literature

> Answers to common questions about CJC-1295: mechanism, DAC half-life extension, Phase 1 trial results, pulsatility preservation, regulatory status, and the distinction between CJC-1295 with and without DAC.

Answers grounded in the primary literature — the Phase 1 trials, the mechanistic reviews, the anti-doping analytical studies, and the available animal data. Slightly warmer in register than the research pages, but still research-attributed throughout.

## The Compound and Its Mechanism

**What is CJC-1295 and how does it differ from native GHRH?**

Native GHRH is a 44-amino acid neuropeptide released from the hypothalamus that travels through the hypothalamic-pituitary portal circulation to bind GHRH receptors on anterior pituitary somatotroph cells and drive pulsatile GH secretion. CJC-1295 is a 30-amino acid synthetic analog of the 1–29 active fragment of GHRH, incorporating four amino acid substitutions and, most importantly, a C-terminal maleimidopropionic acid Drug Affinity Complex (DAC) moiety [1][6]. The key practical difference: native GHRH has a plasma half-life of roughly 10 to 13 minutes due to rapid DPP-IV proteolysis, while CJC-1295's DAC modification allows covalent conjugation to circulating albumin within minutes of injection, extending its plasma half-life to an estimated 5.8 to 8.1 days in human subjects [2][6].

**How does the Drug Affinity Complex (DAC) extend CJC-1295's half-life?**

The DAC moiety is a maleimidopropionic acid group attached to the C-terminus of the peptide. After subcutaneous injection, the maleimide reacts with free thiol groups on circulating plasma albumin — primarily the Cys-34 residue — forming a covalent bond [6]. Albumin, which has a plasma half-life of approximately 19 days and circulates at roughly 40 g/L, then acts as a long-lived pharmacokinetic depot, slowly releasing active CJC-1295 into circulation as albumin is catabolized. The D-Ala substitution at position 2 of the peptide also contributes by blocking the DPP-IV cleavage site that would otherwise rapidly inactivate the free peptide [1]. The combined effect converts a peptide that would otherwise be cleared in under 15 minutes into one that persists in pharmacologically meaningful concentrations for nearly a week.

**What receptor does CJC-1295 bind, and what happens downstream?**

CJC-1295 binds the GHRH receptor (GHRH-R), a class II G-protein-coupled receptor expressed on pituitary somatotroph cells [13]. Upon binding, GHRH-R couples to Gs protein, activating adenylyl cyclase and raising intracellular cAMP. cAMP activates protein kinase A (PKA), which phosphorylates CREB — a transcription factor that then drives GH gene expression by binding cAMP response elements in the GH gene promoter. Simultaneously, cAMP-mediated opening of voltage-dependent L-type calcium channels triggers calcium influx and immediate GH granule exocytosis [13]. Secondary pathways include phospholipase C activation and MAP kinase/ERK signaling [13]. The net result is both immediate GH release (via calcium-triggered granule fusion) and sustained upregulation of GH synthesis (via CREB-mediated transcription).

## Human Trial Data

**What does the research show about CJC-1295's effect on growth hormone and IGF-1 levels?**

The most direct answer comes from the Teichman et al. (2006) Phase 1 study in healthy adults: single subcutaneous injections at 30 or 60 mcg/kg produced 2- to 10-fold increases in mean plasma GH concentrations that remained elevated for 6 or more days, with IGF-1 rising 1.5- to 3-fold and staying above baseline for 9 to 11 days [2]. Multiple-dose regimens sustained IGF-1 elevation for up to 28 days. The high inter-individual variability in GH response — a 2- to 10-fold range — is notable and likely reflects the well-documented variability in endogenous GH pulsatility between individuals.

**Does CJC-1295 preserve natural pulsatile growth hormone secretion?**

Yes, based on the available human data. Ionescu and Frohman (2006) measured GH pulse frequency and magnitude in healthy men receiving 60 or 90 mcg/kg and found neither parameter differed significantly from pre-treatment baseline patterns — despite basal GH rising 7.5-fold and mean GH increasing 46% [3]. This is mechanistically expected: CJC-1295 acts at the upstream GHRH receptor, amplifying the endogenous GH pulse generator's output, while leaving the somatostatin-mediated inhibitory rhythm that sculpts pulse timing intact. This contrasts with exogenous growth hormone administration, which supplies GH directly and eliminates the pulsatile pattern via feedback suppression.

**What doses of CJC-1295 have been studied in human research?**

The Teichman et al. (2006) ascending-dose trial examined 30, 60, 120, and 180 mcg/kg subcutaneous in healthy adults [2]. The Ionescu and Frohman (2006) pulsatility study used 60 and 90 mcg/kg [3]. The Sackmann-Sala et al. (2009) proteomic study used 60 to 90 mcg/kg [5]. These are the three published human studies; all other data are from animal models or in vitro analytical work. No studies have been conducted in growth hormone-deficient patients.

**What happened to Phase 2 clinical development?**

Phase 2 clinical development of CJC-1295 was discontinued following an unrelated adverse event in a trial participant. No human efficacy trials in GH-deficient populations were completed, and no therapeutic indication was filed or approved in any jurisdiction. Commercial development by ConjuChem — the company that developed the DAC technology — ceased. This clinical program termination means the compound's evidence base is limited to Phase 1 pharmacokinetic and pharmacodynamic characterization in healthy adults, with no efficacy or safety data from patient populations.

## Pharmacokinetics and Structure

**What is the difference between CJC-1295 with DAC and CJC-1295 without DAC (Modified GRF 1-29)?**

This distinction is pharmacokinetically fundamental. CJC-1295 with DAC incorporates the maleimidopropionic acid Drug Affinity Complex moiety that enables covalent albumin binding, producing the ~5.8-to-8.1-day half-life described in the Teichman et al. 2006 data [2]. CJC-1295 without DAC — commonly marketed as Modified GRF 1-29 in research supply contexts — retains the four amino acid substitutions (D-Ala2, Ala8, Gly15, Met27) that provide DPP-IV resistance but lacks the albumin-binding group. Its half-life, while longer than native GHRH due to DPP-IV resistance, is substantially shorter than the DAC form — on the order of 30 minutes rather than days. These are pharmacologically distinct compounds, and the human trial data in the published literature all describe the DAC form (CAS 863288-34-0). Conflating the two on the basis of shared research-community nomenclature introduces pharmacokinetic errors.

**Why does the albumin-bound form of CJC-1295 complicate anti-doping detection?**

Standard mass spectrometry-based anti-doping methods are designed to detect free peptide analytes. The CJC-1295-albumin covalent conjugate behaves as a protein, not a free peptide, and is not retained or fragmented in the same analytical pipeline [8]. Immunological detection methods — antibody-based assays such as the immuno-PCR approach validated for equine plasma by Timms et al. (2019) at a detection limit of 0.8 pg/mL [8] — are required for initial screening of the albumin-bound form. Subsequent confirmatory methods using immunoaffinity enrichment coupled with nano-UHPLC-HRMS/MS (Knoop et al. 2016 [9], Coppieters et al. 2022 [11]) achieve detection in urine at limits of 5 to 50 pg/mL. The latest generation orbitrap-based nano-LC method (Ucakturk and Nemutlu 2025) achieves LOD at or below 0.5 ng/mL [17]. Despite these methodological advances, Memdouh et al. (2021) noted that no CJC-1295 has been confirmed positive in WADA-accredited samples to date [10] — attributed partly to the analytical challenges and partly to low urinary concentrations and rapid metabolite degradation.

**How is CJC-1295 related to somatopause research?**

Somatopause refers to the gradual age-related decline in GH secretion and IGF-1 levels that begins in the third decade of life. A 2024 study in elderly hospitalized patients (mean age 82) with low IGF-1 found that the pituitary somatotroph retains secretory capacity in advanced age — 16 of 17 subjects mounted an adequate GH response to GHRH/arginine stimulation, with a peak GH of 14.8 mcg/L (range 2.76–47.4 mcg/L) [18]. The primary driver of somatopause appears to be reduced hypothalamic GHRH output rather than intrinsic pituitary failure, a finding that mechanistically supports the strategy of GHRH analog administration as a research intervention in aged models. CJC-1295 has not been studied in aged human subjects, but the mechanistic framework — a responsive pituitary depleted of endogenous GHRH stimulation — provides the scientific rationale underlying this research direction.

## Regulatory and Combination Research Questions

**What is the regulatory and anti-doping status of CJC-1295?**

CJC-1295 is not approved by the FDA or any regulatory agency for any human therapeutic indication. It is not an FDA-approved compound, has no active IND, and no therapeutic indication has been established. It is listed under Section S2 of the WADA Prohibited List — Peptide Hormones, Growth Factors, Related Substances and Mimetics — and is prohibited at all times (in-competition and out-of-competition) for athletes subject to anti-doping rules [7]. The compound is classified as a research chemical; its sale for human consumption is not permitted in the United States.

**What is the scientific rationale for combining CJC-1295 with ipamorelin in research?**

Ipamorelin is a ghrelin receptor agonist (GH secretagogue receptor 1a, GHSR-1a) that stimulates GH release via a pathway distinct from and complementary to the GHRH receptor pathway. GHRH analogs like CJC-1295 increase GH pulse amplitude by stimulating pituitary somatotrophs via GHRH-R; GH secretagogues like ipamorelin increase GH pulse frequency via GHSR-1a signaling [15]. Together, both pathways contribute to GH secretion through different receptor mechanisms, and their combination produces additive stimulation at the somatotroph level. In a murine glucocorticoid-induced muscle atrophy model, the CJC-1295/ipamorelin combination produced significantly improved maximum tetanic tension compared to vehicle and compared to either compound alone [15]. This combination has not been evaluated in controlled human trials.

**How do age-related changes in GH pulsatility affect CJC-1295 research interpretation?**

Endogenous GH secretion is pulsatile and varies substantially by age, sex, body composition, and sleep quality. The human Phase 1 data for CJC-1295 were collected in healthy young adults — predominantly young men — whose baseline GH pulsatility may differ substantially from elderly subjects, women (who show different GH pulse patterns and amplitudes), or GH-deficient patients [12]. Van Hout and Hearne's netnographic data noted that female users in online communities expressed awareness of gender-specific GH pulse variation as a confounding factor in interpreting response [12]. The generalizability of the Teichman and Ionescu data to populations other than the studied cohorts is therefore uncertain.

**Are there downstream effects of CJC-1295 beyond GH and IGF-1?**

The Sackmann-Sala et al. (2009) proteomic study identified changes in five serum proteins following 60 to 90 mcg/kg CJC-1295 administration in healthy adults: decreased apolipoprotein A1 and transthyretin, and increased beta-hemoglobin, a C-terminal albumin fragment, and an immunoglobulin fragment [5]. A statistically significant correlation between the immunoglobulin/albumin spot intensity and IGF-1 elevation was identified (r2 = 0.668, P = 0.002). The mechanistic and clinical significance of these protein changes — whether they reflect direct GH/IGF-1 axis signaling effects, indirect metabolic perturbations, or albumin-conjugate-specific effects — has not been further characterized in the published literature.

**What long-term safety concerns appear in the literature?**

The published Phase 1 data report no serious adverse reactions at 30 to 60 mcg/kg dose levels in healthy adults over the study periods examined [2]. However, the long-term consequences of sustained GH/IGF-1 elevation in elderly or GH-deficient populations remain incompletely characterized. Known risks of pharmacological GH replacement in adult GHD contexts — fluid retention (11–100%), carpal tunnel syndrome (7–50%), arthralgias (14–77%), and a 3% incidence of type 2 diabetes [16] — provide indirect context about the GH axis activation risk profile, but these effects were characterized under approved GH therapy with continuous GH administration, not GHRH analog stimulation. Potential cardiovascular effects, glucose dysregulation, and long-term cancer risk under sustained IGF-1 elevation from CJC-1295 specifically are uncharacterized in the published literature.

---

An independent scholarly digest of the peer-reviewed CJC-1295 literature — not a clinic, not a vendor, not medical advice.